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Abstract
Staphylococcus aureus carriers with S. aureus bacteremia may have a reduced mortality
risk compared to non-carriers. A role for the immune system is suggested. Here, we study in
mice the effect of mild S. aureus skin infection prior to endogenous or exogenous S. aureus
bacteremia, and evaluate protection in relation to anti-staphylococcal antibody levels. Skin
infections once or twice by a clinical S. aureus isolate (isolate P) or S. aureus strain 8325-4
were induced in mice free of S. aureus and anti-staphylococcal antibodies. Five weeks later,
immunoglobulin G (IgG) levels in blood against 25 S. aureus antigens were determined, and
LD50 or LD100 bacteremia caused by S. aureus isolate P was induced. S. aureus skin infec-
tions led to elevated levels of anti-staphylococcal IgG in blood. One skin infection improved
the course of subsequent severe endogenous bacteremia only. A second skin infection fur-
ther improved animal survival rate, which was associated with increased pre-bacteremia
IgG levels against Efb, IsaA, LukD, LukE, Nuc, PrsA andWTA. In conclusion, S. aureus iso-
late P skin infection in mice reduces the severity of subsequent endogenous S. aureus bac-
teremia only. Although cellular immune effects cannot be rules out, anti-staphylococcal IgG
against specified antigens may contribute to this effect.
Introduction
About 20% of the healthy human population persistently carries Staphylococcus aureus in their
nose [1–3]. Although carriage of S. aureus is usually asymptomatic, this bacterial species can
also cause infections. These include skin and soft tissue infections such as furunculosis, and
also life-threatening invasive diseases such as pneumonia and bacteremia [4]. Nasal carriage of
S. aureus is a major risk factor for the development of surgical site infections caused by S. aure-
us [5–9]. Moreover, Wertheim et al. [10] suggested that carriers have a three-fold higher risk
than non-carriers of acquiring hospital-associated S. aureus bacteremia, while the mortality
risk in carriers with bacteremia might be lower [10][10].
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In spite of the higher risk of acquiring nosocomial S. aureus bacteremia in S. aureus carriers,
the risk of death due to bacteremia might be lower once carriers acquire bacteremia. An expla-
nation for this has not yet been provided, although a role for the immune system has been pro-
posed. More than 80% of health care-associated S. aureus infections are caused by an
endogenous strain [10, 11]. This suggests that because of long-term exposure to the colonizing
S. aureus strain, carriers may have developed antibodies or cellular immune responses that pro-
tect against endogenous bacteremia-related death. Non-carriers may have developed humoral
responses that protect against colonization more than against invasive disease. Several studies
have been conducted comparing anti-staphylococcal antibody levels in carriers and non-
carriers. Carriers show higher immunoglobulin G (IgG) levels than non-carriers against toxic
shock syndrome toxin 1 (TSST-1), staphylococcal enterotoxin A (SEA) [12] and the factor ef-
fecting methicillin resistance (FmtB) [13]. In contrast, compared to carriers, IgG levels in non-
carriers are significantly higher against alpha toxin, major autolysin (Atl), iron-responsive sur-
face determinant A and H (IsdA and IsdH), immunodominant staphylococcal antigen A
(IsaA) [13], extracellular adherence protein (Eap), haptoglobin-hemoglobin binding protein A
(HarA), and clumping factor B (ClfB) [14]. In addition to these descriptive studies, the pro-
spective clinical study of Kolata et al. [15] also suggested a contribution of antibodies against
the colonizing S. aureus strain in the improvement of the course and outcome of S. aureus bac-
teremia. In this study, S. aureus carriers who developed endogenous S. aureus bacteremia
showed a stronger and broader pre-bacteremia IgG response to their own invasive, endogenous
S. aureus strain compared to non-carriers, who develop an exogenous S. aureus bacteremia. Re-
cently, Montgomery et al. [16] showed in an experimental study in mice that S. aureus skin and
soft tissue infection (SSTI) protects against secondary endogenous SSTI. This protection was
mediated by antibody and interleukin (IL) 17A and inhibited by interferon (IFN) γ. Conclu-
sions regarding the antigen-specificity of these antibodies were not drawn. Their observation
suggests, in addition to a role of humoral immunity, a protective role of cellular immunity. Pro-
tection against exogenous infection was not studied.
In humans, conclusive studies on the exact influence of S. aureus carriage and/or S. aureus
exposure and the role of humoral and/or cellular immunity on the course and outcome of sub-
sequent endogenous or exogenous S. aureus infection are difficult as both carriers and non-car-
riers harbor a diversity of anti-staphylococcal antibodies. In non-carriers, these antibodies may
be induced by S. aureus carriage or (sub-)clinical infection in the past. Studies in mice initially
free of S. aureus and anti-staphylococcal antibodies may provide further insight.
In the present study in mice, we investigated whether the course of S. aureus bacteremia is
influenced by prior S. aureus exposure and whether this is dependent on the S. aureus strain
(endogenous or exogenous) causing the initial exposure. For this purpose, a mouse model of
mild S. aureus skin infection once or twice was established. We focused in this study on humor-
al immunity only, by analyzing the pre-bacteremia IgG levels against a broad panel of 25 S. au-
reus antigens following skin infection, and we assessed whether improvement in the course of
S. aureus bacteremia was associated with pre-bacteremia IgG levels.
Materials and Methods
Bacteria
Bacterial strains used were a clinical S. aureus isolate and S. aureus strain 8325–4, a well-
characterized laboratory strain (MSSA, ST8) [17]. S. aureus isolate P (gift from G. Buist, Univer-
sity of Groningen, University Medical Center Groningen, Groningen, the Netherlands) is a clini-
cal isolate recovered from blood of a septic patient and was previously described and analyzed by
proteomics by Ziebandt et al. (community-acquired MSSA, ST7, agr-type 1) [18]. Staphylococci
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were grown overnight at 35°C on Colombia III blood agar (Becton Dickinson, Breda, the Nether-
lands). Cultures of S. aureus, grown in Brain Heart Infusion broth (Becton Dickinson, Breda, the
Netherlands) until OD560 ~ 1.0, were stored with 5% glycerol at -80°C. For infection, a suspen-
sion of staphylococci was defrosted and centrifuged for 10 minutes at 14,000 x g. The S. aureus
pellet was resuspended in saline, and diluted to obtain the desired inoculum.
Animals
Specified opportunistic pathogen-free (SOPF) female BALB/cBYJ mice were obtained from
Charles River (Saint-Germain-sur-l’Arbresle, France). These S. aureus-free animals were 11–13
weeks old on the day of infection, and were given food and water ad libitum. Before each exper-
iment, one mouse per group was sacrificed to confirm the S. aureus-free status in terms of cul-
tures of fresh fecal and nasal microbiota and the absence of anti-staphylococcal IgG levels in
blood (see below). The animal experimental protocols adhered to the rules laid down in the
Dutch Animal Experimentation Act and the EU Animal Directive 2010/63/EU, and the Institu-
tional Animal Care and Use Committee of the Erasmus University Medical Centre Rotterdam
approved the present protocols (permit number: EMC2415).
Model of S. aureus skin infection
The method of induction of S. aureus skin infection in mice was adapted from Brown et al.
[19]. In short, the lower back of the mice was shaved and cleaned with 70% ethanol under gen-
eral anesthesia after using a mixture of medetomidine (Sedator
1
, 0.5 mg/kg; Eurovet Animal
Health, Bladel, the Netherlands), midazolam (Midazolam, 5 mg/kg; Actavis, Baarn, the Nether-
lands) and fentanyl (Fentanyl, 0.05 mg/kg; Hameln Pharmaceuticals, Hameln, Germany).
S. aureus isolate P (3–6 x 107 CFU) or S. aureus 8325–4 (5–10 x 107 CFU) was injected intra-
dermally (50 μL) (n = 10 per group). For placebo skin infection, mice received saline. Anesthe-
sia was antagonized to quickly awaken the mice using a mixture of atipamezole (Antisedan
1
,
2.5 mg/kg; Orion Corporation, Espoo, Finland), flumazenil (Flumazenil, 0.5 mg/kg; Pharma-
chemie, Haarlem, the Netherlands) and naloxon (Naloxon, 1.2 mg/kg; Orpha-Devel Handels
und Vertriebs, Purkersdorf, Germany). Anesthetic and antagonistic agents were administered
intraperitoneally, in a total volume of 175 and 250 μL, respectively. Mouse body weight was as-
sessed three times a week. Two and five weeks after intradermal S. aureus inoculation, blood
was withdrawn from the tail artery to determine anti-staphylococcal IgG levels in serum. Blood
was collected in a Microvette
1
CB300 tube (Sarstedt, Etten-Leur, the Netherlands) and sera
were prepared and stored at -80°C. At week five, mice were sacrificed by CO2 exposure. Pres-
ence of S. aureus in intestines and nasopharynx five weeks after intradermal S. aureus inocula-
tion was determined by culturing fresh feces and nasopharyngeal lavage in phenol-red
mannitol salt broth (PHMB; Becton Dickinson, Breda, the Netherlands) at 35°C for 7 days. Na-
sopharyngeal lavage was performed by flushing the nares with 5 mL sterile phosphate buffered
saline + 0.4% Tween 20 (Sigma-Aldrich, Zwijndrecht, the Netherlands). When PHMB turned
yellow, this was subcultured overnight at 35°C on Colombia III blood agar. S. aureus was iden-
tified based on colony morphology and Slidex Staph Plus agglutination testing (bioMérieux,
Marcy l’Etoile, France). Multi-locus variable number of tandem repeat analysis (MLVA) of
SIRU01, SIRU07, SIRU13 and SIRU15 [20] was used at regular intervals to verify that isolated
S. aureus strains were the same as the strain used for infection of mice.
Model of S. aureus bacteremia
Bacteremia was induced by inoculation of 100 μL of S. aureus isolate P into the tail vein. A S.
aureus inoculum at the 50% lethal dose (LD50; 1–2 x 105 CFU) or at the 100% lethal dose
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(LD100; 5–8 x 105 CFU) was used for establishment bacteremia. Clinical signs of illness in each
mouse were evaluated twice daily during the experiment to minimize suffering as described be-
fore [21]. Mice were scored -1 directly after bacterial inoculation. Mice with bad fur were
scored -2. Mice with bad fur and hunched back were scored -3. Mice with bad fur and hunched
back and that showed instability were scored -4. These mice showed severe signs of illness and
were euthanized by CO2 exposure. Euthanized mice were considered as deaths, as pilot experi-
ments showed that mice with severe signs of illness die before the next time point. Animal sur-
vival rate over 14 days after infection was monitored. At day 28, S. aureus load in blood and
organs of surviving animals was determined to investigate whether surviving mice next to sur-
vival also showed improved S. aureus clearance. The mice were sacrificed by CO2 exposure. A
blood sample was taken via a transcutaneous cardiac puncture and collected in a vial contain-
ing Lithium Heparin (Sarstedt, Etten-Leur, the Netherlands). The lungs, spleen, liver, and kid-
neys were removed aseptically and homogenized (Polytron, Kinematica, Luzern, Switzerland)
in 2 mL of saline for 10 seconds at 30,000 rpm at room temperature. Undiluted homogenate
suspensions and blood as well as 10-fold serial dilutions in saline were plated onto Colombia
III blood agar. After incubation overnight at 35°C, colonies were counted.
Experimental set-up to study the course of S. aureus bacteremia in
relation to prior S. aureus skin infection
Experimental set-up is shown in Fig 1. Skin infection with S. aureus isolate P or with S. aureus
8325–4 (n = 15 per group) was induced 35 days before induction of bacteremia. Controls re-
ceived intradermal inoculation of saline. In case of skin infection twice, three weeks after the
first skin infection, a second skin infection using the same S. aureus strain was applied, near the
Fig 1. Experimental set-up for studying the influence of S. aureus skin infection on subsequent bacteremia. A. Skin infection once at 35 days before
S. aureus bacteremia. B. Skin infection twice at 35 days and 14 days before S. aureus bacteremia.
doi:10.1371/journal.pone.0129150.g001
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inoculation site of the first skin infection. Bacteremia caused by S. aureus isolate P was always
established at five weeks after the first skin infection, when mice were 16–18 weeks old (adults).
Quantification of serum anti-staphylococcal IgG levels
Serum IgG levels against the following antigens were semi-quantified: alpha toxin; clumping fac-
tors A and B (ClfA and ClfB); extracellular fibrinogen-binding protein (Efb); ESAT-6-like pro-
tein (EsxA) and CFP-10-like protein (EsxB); formyl peptide receptor-like1 inhibitory protein
(FLIPr); fibronectin-binding protein A (FnbpA); immunodominant staphylococcal antigen A
(IsaA); iron-responsive surface determinants A and H (IsdA and IsdH); lipase; leukocidins D
and E (LukD and LukE); peptidoglycan hydrolase (LytM); endonuclease (Nuc); peptidoglycan
(PG); a parvulin-type peptidyl-prolyl cis/trans isomerase (PrsA); hypothetical protein SA0104;
serine-aspartate dipeptide repeat protein D (SdrD); staphylococcal superantigen-like proteins 1,
3, 5, and 10 (SSL1, SSL3, SSL5, and SSL10); and wall teichoic acid (WTA). Genes encoding these
S. aureus antigens were all present in both S. aureus isolate P and S. aureus 8325–4.
Alpha toxin, LukD, and LukE were prepared as described previously [22]. ClfB, FnbpA,
IsdA, IsdH, and SdrD were expressed and purified as described previously [12]. The constructs
were kindly provided by T. Foster (Trinity College, Dublin, Ireland). All other antigens were
kindly provided by other research groups, as indicated in the Acknowledgements.
IgG levels were semi-quantified simultaneously in multiplex assays using a bead-based flow
cytometry technique (xMap; Luminex Corporation, Austin, TX). Methods have been described
elsewhere [23–26]. Tests were performed in independent duplicates, and the median fluores-
cence intensity (MFI) values, reflecting semi-quantitative antibody levels, were averaged. In
each experiment, control beads (no antigen coupled) were included to determine nonspecific
binding. In case of nonspecific binding, the nonspecific MFI values were subtracted from the
antigen-specific values.
Serum samples from mice with skin infection caused by S. aureus isolate P or S. aureus
8325–4 (n = 10 per group), and from mice with placebo skin infection were analyzed. Sera
from three non-infected mice were used as negative controls.
Statistical analysis
The Mann-Whitney U test was used to compare median differences in anti-staphylococcal IgG
levels in different groups. The Wilcoxon Signed Rank test was used to compare anti-
staphylococcal IgG levels in paired samples. In individual mice, high IgG levels against an anti-
gen were not correlated with high IgG levels against other antigens, or vice versa. The Bonfer-
roni correction was applied to correct for multiple testing. As a result, P-values< 0.002 were
considered to be statistically significant. These statistical analyses were performed using the
Statistical Package of Social Sciences version 17.0 for Windows (SPSS Inc., Chicago, IL).
The Fisher’s exact test was used to compare differences in S. aureus colonization status. The
log rank test was used to determine statistical differences in animal survival rate between
groups. Differences were considered statistically significant when 2-sided P-values
were< 0.05. GraphPad Prism 5 for Windows (GraphPad Software Inc., La Jolla, CA) was used
for these statistical analyses.
Results
S. aureus skin infection
Mice infected with S. aureus isolate P or S. aureus 8325–4 developed a scab (area of ~1.5 cm2)
at the inoculation site within 1 week. Body weight loss was only minor (maximum of 8% at
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week 1 after intradermal inoculation) and mice appeared healthy. Five weeks after infection,
when S. aureus bacteremia was induced, the skin had healed and body weight was restored.
S. aureus cultures from the inoculation site were always negative at week 5 after skin infection.
However, the intestines of mice with skin infection once or twice, caused by S. aureus isolate P
or S. aureus 8325–4, were always culture positive for the infecting S. aureus strain. Nasopha-
rynges were not always culture positive: S. aureus was cultured from mice after S. aureus isolate
P skin infection once (3 of 10 mice) or twice (5 of 10 mice), and after S. aureus 8325–4 skin in-
fection once (1 of 10 mice) or twice (4 of 10 mice). No significant differences in number of na-
sopharynx culture positive mice were observed.
Anti-staphylococcal IgG levels following skin infection
Serum anti-staphylococcal IgG levels against a broad panel of 25 staphylococcal antigens were
assessed in mice with S. aureus isolate P skin infection once or twice (Table 1) or with S. aureus
8325–4 skin infection once or twice (Table 2) (n = 10 per group). Levels were assessed at two
and five weeks after the first skin infection. Antigens included immune modulators, superanti-
gen like proteins, MSCRAMMs (microbial surface components recognizing adhesive matrix
molecules), toxins, and household antigens. Before infection (week 0), IgG levels were at back-
ground values. In mice with skin infection once caused by S. aureus isolate P or S. aureus
8325–4, IgG levels against a number of S. aureus antigens were observed at week 2 and 5 after
infection, but these did not change significantly over time. However, following the second skin
infection with S. aureus isolate P, the IgG levels against IsaA, Nuc, PrsA, and WTA were signif-
icantly elevated at week 5 (P< 0.002), whereas the second skin infection with S. aureus 8325–4
resulted in a significant rise in IgG levels at week 5 against Efb, IsaA, and IsdA (P< 0.002).
Course of S. aureus bacteremia in mice with prior skin infection
Bacteremia was always induced by S. aureus isolate P irrespective of the strain used for skin in-
fection. Animal survival rate after bacteremia was monitored over a 14-day evaluation period.
After this time point, no further changes in animal survival were observed (data not shown).
The course of LD50 S. aureus bacteremia in mice with prior skin infection is shown in Fig
2A and 2B (n = 15 per group). In mice with placebo skin infection, survival of bacteremic mice
declined gradually, until 47–73% at day 14. Survival rates of mice with placebo skin infection
once or twice were comparable. After skin infection once or twice with S. aureus isolate P or
S. aureus 8325–4, animal survival rate of bacteremic mice was not significantly improved com-
pared to placebo skin infection.
The course of LD100 S. aureus bacteremia in mice with prior skin infection is shown in Fig
2C and 2D (n = 15 per group). In mice with placebo skin infection, survival of bacteremic mice
declined gradually, and at day 6 all mice had died. Survival rates of mice with placebo skin in-
fection once or twice were comparable. An increased animal survival rate of bacteremic mice
was observed only after prior skin infection with S. aureus isolate P. The time to death of bac-
teremic mice was increased after skin infection once (P = 0.033), and was further prolonged
after the second skin infection (P = 0.001). Mouse survival at day 14 was increased from 0% to
20%. Skin infection once or twice with S. aureus 8325–4 had no effect on the course
of bacteremia.
In mice that survived LD50 bacteremia (Fig 2A and 2B) or LD100 bacteremia (Fig 2D),
S. aureus was never cultured from blood, lungs, spleen, and liver at day 28. In 17–60% of sur-
viving mice, cultures from kidneys were S. aureus positive, ranging from 1 x 101–2 x 107 CFU
per two kidneys, but differences in number of S. aureus positive kidneys between the mice that
survived moderate bacteremia were not observed
S. aureus Bacteremia after Prior S. aureus Skin Infection
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Course of S. aureus bacteremia in association with anti-S. aureus IgG
levels
We assessed whether improvement of the course of S. aureus bacteremia was associated with
increased levels of anti-staphylococcal IgG induced by S. aureus skin infection. To this aim, in
mice receiving skin infection twice caused by S. aureus isolate P or S. aureus 8325–4 (n = 10
per group), serum IgG levels against a broad panel of 25 staphylococcal antigens at week 5 after
skin infection, the day of induction of S. aureus isolate P bacteremia were compared. IgG levels
Table 1. S. aureus isolate P skin infection. Median fluorescence intensity (MFI) values reflecting levels of antigen-specific IgG against 25 S. aureus anti-
gens in sera frommice (n = 10 per group) before skin infection (week 0), after skin infection once (week 2 and week 5), and after skin infection twice (week 5
after first skin infection).
Skin infection once Skin infection
twice
Antigen Median
MFI week
0 (range)
Median MFI
week 2 (range)
Median MFI week
5 (range)
Median MFI week
5 (range)
P-value (skin
infection
once) week 2
vs week 0a
P-value (skin
infection
once) week 5
vs week 0a
P-value (skin
infection
once) week 5
vs week 2b
P-value
(week 5) skin
infection
twice vs
oncea
alpha
toxin
0 (0–1) 644 (203–1712) 5693 (4402–6704) 3994 (3381–5922) 0.011 0.011 0.005 0.007
ClfA 0 (0–0) 0 (0–0) 0 (0–4) 0 (0–5) 1.000 0.584 0.317 0.304
ClfB 0 (0–0) 0 (0–0) 0 (0–14) 0 (0–4) 1.000 0.584 0.317 0.358
Efb 3 (1–6) 4 (2–8) 11 (7–1536) 143 (33–1590) 0.611 0.011 0.005 0.070
EsxA 5 (5–6) 5 (5–6) 6 (4–8) 5 (3–8) 0.661 0.495 0.313 0.569
EsxB 3 (3–4) 4 (3–24) 5 (3–46) 4 (2–177) 0.551 0.062 0.028 0.119
FLIPr 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–44) 1.000 1.000 1.000 0.068
FnbpA 0 (0–0) 0 (0–3) 0 (0–14) 0 (0–0) 0.584 0.584 0.317 0.317
IsaA 5 (4–6) 12 (6–1504) 8 (5–1509) 3885 (247–8090) 0.014 0.034 0.386 0.001 *
IsdA 103 (3–
106)
77 (0–108) 30 (0–94) 70 (0–432) 0.498 0.236 0.012 0.072
IsdH 63 (27–
68)
38 (21–61) 36 (11–50) 41 (20–1065) 0.236 0.236 0.475 0.257
lipase 6 (6–6) 9 (8–14) 8 (7–20) 80 (9–8188) 0.011 0.011 0.959 0.002
LukD 0 (0–0) 0 (0–0) 103 (1–1986) 1595 (34–5177) 0.584 0.011 0.005 0.019
LukE 2 (0–2) 235 (13–777) 4470 (2110–6930) 6487 (4921–7596) 0.011 0.011 0.005 0.023
LytM 1 (1–3) 2 (0–5) 2 (1–3) 4 (2–66) 0.865 0.441 0.918 0.015
Nuc 2 (1–3) 6 (0–270) 405 (2–3999) 4554 (930–5686) 0.128 0.028 0.013 0.001 *
PG 6 (4–6) 6 (5–6) 6 (5–7) 6 (5–7) 0.302 0.395 0.777 0.223
PrsA 32 (28–
33)
405 (194–900) 3282 (1728–4490) 4568 (3592–5838) 0.011 0.011 0.005 0.0019 *
SA0104 5 (4–6) 6 (4–19) 6 (4–34) 6 (5–9) 0.125 0.106 0.574 0.939
SdrD 0 (0–0) 0 (0–10) 0 (0–22) 0 (0–5) 0.584 0.584 0.317 0.942
SSL1 0 (0–0) 0 (0–50) 1 (0–63) 21 (0–34) 0.215 0.148 0.500 0.292
SSL3 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1.000 1.000 1.000 1.000
SSL5 0 (0–0) 0 (0–2) 3 (0–274) 0 (0–20) 0.584 0.098 0.028 0.033
SSL10 0 (0–0) 0 (0–2) 1 (0–12) 0 (0–2) 0.147 0.098 0.324 0.606
WTA 1 (0–1) 1 (0–2) 4 (2–10) 22 (4–78) 0.283 0.011 0.008 0.0019 *
a Mann-Whitney U test
b Wilcoxon signed ranks test
* P < 0.002
doi:10.1371/journal.pone.0129150.t001
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are shown in Fig 3. In S. aureus isolate P skin infected mice, IgG levels against alpha toxin, Efb,
EsxA, EsxB, IsaA, IsdA, IsdH, lipase, LukD, LukE, LytM, Nuc, PG, PrsA, and SA0104 were sig-
nificantly higher than in mice with placebo skin infection. In S. aureus 8325–4 skin infected
mice, IgG levels against Efb, EsxA, EsxB, IsaA, IsdA, IsdH, lipase, LukD, LukE, LytM, Nuc, PG,
PrsA, SA0104, SSL1 and SSL10 were significantly higher than in mice with placebo skin infec-
tion. Comparing both IgG profiles, IgG levels against Efb, LukD, LukE, Nuc, and WTA were
significantly higher in S. aureus isolate P skin infected mice than in S. aureus 8325–4 skin
infected mice.
Table 2. S. aureus 8325–4 skin infection. Median fluorescence intensity (MFI) values reflecting levels of antigen-specific IgG against 25 S. aureus antigens
in sera frommice (n = 10 per group) before skin infection (week 0), after skin infection once (week 2 and week 5), and after skin infection twice (week 5 after
first skin infection).
Skin infection once Skin infection
twice
Antigen Median
MFI week
0 (range)
Median MFI
week 2 (range)
Median MFI week
5 (range)
Median MFI week
5 (range)
P-value (skin
infection
once) week 2
vs week 0a
P-value (skin
infection
once) week 5
vs week 0a
P-value (skin
infection
once) week 5
vs week 2b
P-value
(week 5) skin
infection
twice vs
oncea
alpha
toxin
0 (0–1) 1129 (354–2341) 5545 (2110–6932) 4401 (2878–6605) 0.011 0.011 0.005 0.258
ClfA 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 1.000 0.584 0.317 0.317
ClfB 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–2) 1.000 1.000 1.000 0.317
Efb 3 (1–6) 4 (2–8) 8 (6–12) 24 (15–80) 0.445 0.017 0.009 0.0002 *
EsxA 5 (5–6) 5 (3–6) 6 (4–6) 6 (5–6) 0.865 0.670 0.366 0.335
EsxB 3 (3–4) 3 (3–12) 4 (3–6) 4 (2–39) 0.733 0.351 0.483 0.731
FLIPr 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1.000 1.000 1.000 1.000
FnbpA 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–2) 1.000 1.000 1.000 0.147
IsaA 5 (4–6) 7 (4–61) 6 (5–166) 186 (12–6838) 0.235 0.089 0.918 0.001 *
IsdA 103 (3–
106)
54 (0–129) 82 (0–221) 525 (120–1145) 0.397 0.612 0.161 0.001 *
IsdH 63 (27–
68)
34 (28–60) 36 (14–53) 37 (19–61) 0.398 0.237 0.359 0.650
lipase 6 (6–6) 12 (5–166) 141 (8–1992) 405 (8–6865) 0.011 0.011 0.008 0.364
LukD 0 (0–0) 0 (0–61) 7 (0–112) 11 (2–57) 0.304 0.037 0.012 0.325
LukE 2 (0–2) 5 (0–345) 57 (5–1008) 118 (7–1743) 0.034 0.011 0.022 0.364
LytM 1 (1–3) 2 (1–3) 2 (1–3) 3 (1–22) 0.492 0.293 0.429 0.333
Nuc 2 (1–3) 1 (0–13) 2 (0–15) 11 (1–1646) 0.497 0.670 0.130 0.031
PG 6 (4–6) 6 (5–6) 6 (4–7) 6 (5–7) 0.664 0.389 0.589 0.373
PrsA 32 (28–
33)
190 (43–303) 1074 (153–2502) 3167 (264–4967) 0.011 0.011 0.005 0.034
SA0104 5 (4–6) 6 (5–8) 5 (4–8) 7 (4–23) 0.034 0.391 0.087 0.030
SdrD 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–3) 1.000 1.000 1.000 0.317
SSL1 0 (0–0) 1 (0–93) 45 (0–3834) 41 (1–4112) 0.148 0.062 0.043 0.545
SSL3 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1.000 1.000 1.000 1.000
SSL5 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–5) 1.000 1.000 1.000 0.317
SSL10 0 (0–0) 0 (0–5) 0 (0–6) 1 (0–5) 0.215 0.148 0.564 0.209
WTA 1 (0–1) 1 (0–2) 2 (0–7) 3 (1–12) 0.122 0.383 0.443 0.068
a Mann-Whitney U test
b Wilcoxon signed ranks test
* P < 0.002
doi:10.1371/journal.pone.0129150.t002
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Discussion
In the present study, we showed for the first time that mild S. aureus skin infection improved
the course of subsequent endogenous S. aureus bacteremia. The use of S. aureus-free mice en-
abled us to draw conclusions in this respect. In humans, conclusive studies on the exact influ-
ence of S. aureus exposure on the outcome of S. aureus bacteremia remain difficult, as both
carriers and non-carriers have been exposed to S. aureus [12–15]. Wertheim et al. [10] already
showed that carriers may have a decreased risk of death due to S. aureus bacteremia compared
to non-carriers, hypothesizing that anti-staphylococcal antibody levels or components of the
cellular immune system that are increased in carriers, induced by prior S. aureus exposure,
may play a role in protection against death due to S. aureus bacteremia. Our observations in
the present study in mice are in line with the suggestions made by Wertheim et al.
Fig 2. Survival rate in mice with S. aureus bacteremia. Skin infection prior to S. aureus bacteremia was induced once or twice by S. aureus isolate P (red
squares) or S. aureus 8325–4 (green triangles); placebo skin infection (black circles). LD50 or LD100 bacteremia was induced by S. aureus isolate P. Animal
survival rate in different groups (n = 15 per group) was compared using the log-rank test, and P-values are indicated in the table. Stars indicate statistically
significant differences (P < 0.05).
doi:10.1371/journal.pone.0129150.g002
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We established local S. aureus skin infection caused by either S. aureus isolate P, a clinical
sepsis isolate [18], or S. aureus 8325–4, a frequently used sequenced strain [17]. Subsequent
bacteremia was always induced by S. aureus isolate P. Skin infection led to S. aureus coloniza-
tion in intestines and nasopharynges, and with respect to the humoral immune response, anti-
staphylococcal IgG in blood was found. The skin infection described above was mild and tran-
sient, simulating a mild S. aureus infection in humans. We showed that prior S. aureus skin in-
fection improved the course of LD100 S. aureus isolate P bacteremia provided that bacteremia
was caused by the endogenous S. aureus strain. This effect was not observed in exogenous bac-
teremia caused by S. aureus isolate P when skin infection was induced by S. aureus 8325–4.
While a single prior skin infection resulted in delayed time to death and improved animal sur-
vival in our endogenous LD100 S. aureus bacteremia model, in endogenous LD50 S. aureus
bacteremia prior skin infection did not. This lack of a protective effect in LD50 S. aureus bac-
teremia may be related to the relatively small window to detect significant differences in this re-
spect. Whereas in the present study bacteremia was always caused by S. aureus isolate P, in
Fig 3. Antigen-specific IgG levels in mice at week 5 after S. aureus skin infection twice.Median fluorescence intensity (MFI) values reflect levels of IgG
against 25 S. aureus antigens. Skin infections were induced by S. aureus isolate P (red squares) or S. aureus 8325–4 (green triangles); placebo skin infection
(black circles) (n = 10 per group). Median values are indicated by horizontal lines. Stars indicate significant differences (P < 0.002) between mice with S.
aureus isolate P skin infection and mice with placebo skin infection. Number signs indicate significant differences (P < 0.002) between mice with S. aureus
8325–4 skin infection and mice with placebo skin infection. Dollar signs indicate significant differences (P < 0.002) between mice with S. aureus isolate P skin
infection and mice with S. aureus 8325–4 skin infection.
doi:10.1371/journal.pone.0129150.g003
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future experiments it would be informative to study the effects of skin infection on the course
and outcome of subsequent S. aureus 8325–4 bacteremia. S. aureus 8325–4 showed a very steep
inoculum-response curve in the mouse model of bacteremia, and as a consequence unfortu-
nately, we were not able to realize reproducible infection models with LD50 and LD100
inocula.
We also demonstrated that a second skin infection following the first skin infection further
enhanced the survival rate in mice with endogenous LD100 S. aureus bacteremia. Also in the
model of endogenous LD50 S. aureus bacteremia, mortality was reduced, although this differ-
ence was only borderline significant (P = 0.052), indicating a trend in improvement of survival
rate in skin infected mice with subsequent endogenous bacteremia. Interestingly, following the
second skin infection, pre-bacteremia serum IgG levels were elevated as well. As improved sur-
vival rates were associated with strong increases in pre-bacteremia anti-staphylococcal IgG lev-
els, this suggests that IgG resulting from prior mild skin infection may potentially act
protective against antigens determining the outcome of S. aureus bacteremia. Future studies in-
cluding successful adoptive transfer of antibody purified from serum of skin infected mice to
naive mice prior to S. aureus bacteremia are necessary to confirm a protective role of pre-
bacteremia IgG.
Regarding the pre-bacteremia IgG levels, most striking were the IgG levels against IsaA,
Nuc, PrsA, and WTA, which were further elevated following the second skin infection. These
IgG levels may contribute to the delayed time to death and improved animal survival in mice
with S. aureus isolate P bacteremia. Next to IgG against these S. aureus antigens, pre-
bacteremia IgG against Efb, LukD, and LukE may also contribute in this respect. These IgG lev-
els were elevated in mice with S. aureus isolate P skin infection twice and endogenous bacter-
emia compared to mice with S. aureus 8325–4 skin infection twice and exogenous bacteremia.
Our observation that S. aureus isolate P skin infection improved the course of subsequent
endogenous S. aureus bacteremia in mice are in line with those obtained in a recently published
experimental study in mice by Montgomery et al. [16]. They studied the effect of S. aureus
SF8300 (USA300) skin infection (SSTI) on a secondary SSTI caused by the same S. aureus
strain. It was shown that skin infection protected against the subsequent skin infection. Protec-
tion against exogenous SSTI was not studied. They demonstrated that this protection was me-
diated by antibody and IL-17A and inhibited by IFN-γ as shown by antibody transfer to naive
mice and neutralization of IL-17A or IFN-γ prior to infection, respectively. While in their
study IgG levels against Hla and IsdB were assessed, the present study in mice included IgG lev-
els against a broad panel of 25 S. aureus antigens. Future studies in mice on the effect of immu-
nization targeting IsaA, Nuc, PrsA, WTA, Efb, LukD and LukE prior to the induction of
S. aureus bacteremia may shed further light on the protective role of these anti-staphylococcal
IgGs in bacteremia. In addition to these antigens, antibodies against S. aureus antigens not in-
cluded in the present study may also be associated with protection against S. aureus bacteremia.
Further insight may be obtained from adoptive antibody transfer studies.
Next to the potential role of pre-bacteremia anti-staphylococcal antibodies, components of
cellular immunity are expected to contribute as well to the improvement of the animal survival
rate in mice with endogenous S. aureus bacteremia, as the cellular immune response has a role
in S. aureus infections [16, 27, 28]. Regarding the role of cellular immunity in reduction of
S. aureus bacteremia-related mortality, conclusions cannot be drawn from the present study
which was focused on the humoral immune response prior to S. aureus bacteremia. However
Montgomery et al. [16] showed that in their model of SSTI protection against the second skin
infection in BALB/c mice was mediated by both antibody and IL-17A. It would be very inter-
esting to investigate the role of IL-17A and other components of cellular immunity in the S. au-
reus bacteremia model used in the present study.
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In addition to pre-bacteremia immune responses, the consequences of exposure to S. aureus
in the intestines and nasopharynx following S. aureus skin infection may also contribute to the
improvement of the animal survival rate. As differences in number of intestine or nasopharynx
culture positive mice were not observed between the groups, no conclusions can be drawn on
the immunological relevance of colonization of these sites. As quantitative cultures from the in-
testinal and nasopharyngeal flora were not performed, definite conclusions on the role of intes-
tinal and nasopharyngeal colonization cannot be drawn, but this merits further investigation.
In conclusion, we show that S. aureus isolate P skin infection prior to S. aureus bacteremia
improved the outcome of endogenous invasive infection. Improved animal survival rates may
be associated with the elevated levels of anti-staphylococcal IgGs against specified antigens.
The observation that anti-S. aureus IgG may contribute to improvement of the course and out-
come of endogenous S. aureus bacteremia opens new perspectives to investigate the protective
capacity of active and passive immunization as a non-antibiotic-based treatment regimen in
patients with S. aureus bacteremia. Further studies using other S. aureus strains are needed to
generalize and support our conclusion that S. aureus skin infection improves the course of sub-
sequent endogenous S. aureus bacteremia. In this respect, also the role of cellular immunity
should be further investigated.
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